SQI Diagnostics to Extend Warrant Expiry Date



    TORONTO, June 12 /CNW/ - SQI Diagnostics Inc. (the "Corporation")
(TSX-Venture: SQD), a medical systems automation company focused on evolving
laboratory-based biomarker testing, announced today that it has received
approval from the TSX Venture Exchange to extend the expiry date of 1,783,776
outstanding common share purchase warrants (the "Warrants") of the
Corporation, which were issued in connection with the Corporation's June 2007
private placement financing.
    Each Warrant, as amended, entitles the holder thereof to purchase one
common share of the Corporation at any time until the close of business on
June 29, 2009 at an exercise price of $2.40 per common share. The Warrants
will be amended, effective June 29, 2009, to extend the term of such Warrants
until June 29, 2010. All other provisions of the Warrants will remain the
same. There are two insiders of the Corporation who hold a total of 117,500
Warrants.

    About SQI Diagnostics

    SQI Diagnostics is a medical systems company that develops proprietary
technology in multiplexing, miniaturization and automation. SQI provides
laboratories the ability to simultaneously analyze multiple biomarkers,
deliver accurate and quantitative patient results in less time, significantly
reduce labor, and increase profits...All in One Drop. Please visit
www.sqidiagnostics.com for more information.

    Certain information in this press release is based on beliefs and
assumptions of the Company's senior management and information currently
available to it that may constitute forward-looking information within the
meaning of securities laws. Such statements reflect the current views of the
Company with respect to future events and are subject to certain risks and
uncertainties. Actual results, events, and performance may differ materially.
Readers are cautioned not to place undue reliance on these forward-looking
statements.

    
    This release was prepared by management of the Company who takes full
    responsibility for its contents. The TSX Venture Exchange has not
    reviewed and does not accept responsibility for the adequacy or accuracy
    of this news release.
    

    %SEDAR: 00021000E




For further information:

For further information: Chief Financial Officer: Andrew Morris, (416)
674-9500 ext. 229, amorris@sqidiagnostics.com; Media and Investor Relations:
Adam Peeler, (416) 815-0700 ext. 225, apeeler@equicomgroup.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890